Compare NXPI & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXPI | BDX |
|---|---|---|
| Founded | 2006 | 1897 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8B | 55.5B |
| IPO Year | 2010 | 1962 |
| Metric | NXPI | BDX |
|---|---|---|
| Price | $232.02 | $201.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $246.00 | $205.25 |
| AVG Volume (30 Days) | ★ 2.4M | 1.5M |
| Earning Date | 02-02-2026 | 02-05-2026 |
| Dividend Yield | 1.74% | ★ 2.08% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.08 | 5.82 |
| Revenue | $12,045,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | N/A | $4.01 |
| Revenue Next Year | $9.06 | $3.38 |
| P/E Ratio | ★ $28.75 | $34.67 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $148.09 | $162.29 |
| 52 Week High | $255.45 | $251.99 |
| Indicator | NXPI | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 50.49 |
| Support Level | $228.76 | $203.13 |
| Resistance Level | $241.10 | $207.60 |
| Average True Range (ATR) | 7.23 | 5.02 |
| MACD | -1.07 | -0.23 |
| Stochastic Oscillator | 36.28 | 48.25 |
NXP Semiconductors is a leading supplier of high-performance mixed-signal products. The firm acquired Freescale Semiconductor in 2015 and now has significant market share in the automotive market, where it supplies microcontrollers and analog chips into automotive clusters, powertrains, infotainment systems, and radars. NXP Semiconductors also serves industrial and Internet of Things, mobile, and communications infrastructure.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.